Core Viewpoint - The company is experiencing short-term revenue pressure but demonstrates resilience in gross margin, with strategic adjustments in response to industry competition and consumer fatigue [1][2]. Financial Performance - Total revenue for H1 2025 is 2.372 billion (down 15.4% YoY), with net profit attributable to shareholders at 247 million (down 49.0% YoY) and net profit excluding non-recurring items at 183 million (down 56.5% YoY) [1]. - Gross margin and net profit margin stand at 76.0% and 10.5% respectively (up 3.4 percentage points and down 6.5 percentage points YoY) [1]. - Expense ratios for sales, management, and R&D are 54.2%, 8.1%, and 4.9% respectively (increased by 8.6, 1.9, and 0.8 percentage points YoY) [1]. Revenue Breakdown - Online channel revenue is 1.743 billion (down 6% YoY), with emerging content e-commerce platforms like Douyin showing growth; self-operated channels enhance repurchase rates through tiered membership operations, adding 430,000 new registered users [1]. - OMO channel revenue is 191 million (down 10% YoY) [1]. - Offline channel revenue is 424 million (down 42% YoY) [1]. Strategic Initiatives - The company is optimizing product structure and enhancing membership operations to improve gross margin, focusing on core products and reducing ineffective promotions [2]. - A multi-brand strategy is being deepened, with new growth avenues opened through the expansion of product lines and the acquisition of brands to cover various market segments [2]. - R&D efforts are concentrated on collaborative medical research and clinical efficacy validation, while channel strategies are shifting towards user operation and brand experience centers [2]. Investment Outlook - The company is positioned as a leader in effective skincare, with expected gradual recovery in performance driven by brand matrix, R&D barriers, and channel development [3]. - Projected net profits for 2025-2027 are 547 million, 642 million, and 777 million respectively, with a target valuation of 20.23 billion and a target price of 47.75 [3].
贝泰妮(300957)2025年中报点评：品牌矩阵与研发创新蓄力长期复苏